A Phase 3 Study of CS-8958 (Prophylaxis for children) - A randomized, double-blind, placebo-controlled study to evaluate the efficacy for the prevention of influenza virus infection in children under 10 years

Single 20-mg dose of inhaled CS-8958 20 mg was effective as post-exposure prophylaxis to protect against influenza in pediatric (<10 years of age) household members of index cases for prophylaxis of influenza. Adverse events in CS-8958 20 mg single-dose group did not differ significantly from those in the placebo-group. No abnormal behaviors were observed, and there were no other major safety issues.